famotidine has been researched along with Behavior Disorders in 1 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Famotidine dosage adjustment is required in patients with chronic kidney disease." | 1.33 | Use of famotidine in adult patients with end-stage renal disease: assessment of dosing and mental status changes. ( Hudson, JQ; Nolan, SF; Pentapaty, N; Redmond, AM; Self, T; Weibel, J, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Redmond, AM | 1 |
| Pentapaty, N | 1 |
| Weibel, J | 1 |
| Nolan, SF | 1 |
| Hudson, JQ | 1 |
| Self, T | 1 |
1 other study available for famotidine and Behavior Disorders
| Article | Year |
|---|---|
Use of famotidine in adult patients with end-stage renal disease: assessment of dosing and mental status changes.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Famotidine; Female; Histamine H2 Antagonists; Humans; | 2005 |